CA3201145A1 - Oligonucleotides antisens c-myc et ses procedes d'utilisation pour le traitement de troubles de la proliferation cellulaire - Google Patents

Oligonucleotides antisens c-myc et ses procedes d'utilisation pour le traitement de troubles de la proliferation cellulaire

Info

Publication number: CA3201145A1
Authority: CA; Canada
Prior art keywords: oligonucleotide; seq; myc; cell; linkages
Prior art date: 2012-10-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA3201145A

Other languages

English (en)

Inventor

Sergei M. Gryaznov

Daria Zielinska

Ronald A. Pruzan

Jeffrey N. Lindquist

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Geron Corp

Original Assignee

Geron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-26

Filing date

2013-10-25

Publication date

2014-05-01

2013-03-14 Priority claimed from US13/829,594 external-priority patent/US9228189B2/en

2013-10-25 Application filed by Geron Corp filed Critical Geron Corp

2014-05-01 Publication of CA3201145A1 publication Critical patent/CA3201145A1/fr

Status Pending legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA3201145A 2012-10-26 2013-10-25 Oligonucleotides antisens c-myc et ses procedes d'utilisation pour le traitement de troubles de la proliferation cellulaire Pending CA3201145A1 (fr)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201261719348P	2012-10-26	2012-10-26
US61/719,348		2012-10-26
US201361784910P	2013-03-14	2013-03-14
US13/829,594 US9228189B2 (en)	2012-10-26	2013-03-14	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US13/829,594		2013-03-14
US61/784,910		2013-03-14
CA2887702A CA2887702C (fr)	2012-10-26	2013-10-25	Oligonucleotides antisens c-myc et ses procedes d'utilisation pour le traitement de troubles de la proliferation cellulaire

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2887702A Division CA2887702C (fr)	2012-10-26	2013-10-25	Oligonucleotides antisens c-myc et ses procedes d'utilisation pour le traitement de troubles de la proliferation cellulaire

Publications (1)

Publication Number	Publication Date
CA3201145A1 true CA3201145A1 (fr)	2014-05-01

Family

ID=53002976

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CA2887702A Active CA2887702C (fr)	2012-10-26	2013-10-25	Oligonucleotides antisens c-myc et ses procedes d'utilisation pour le traitement de troubles de la proliferation cellulaire
CA3201145A Pending CA3201145A1 (fr)	2012-10-26	2013-10-25	Oligonucleotides antisens c-myc et ses procedes d'utilisation pour le traitement de troubles de la proliferation cellulaire

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CA2887702A Active CA2887702C (fr)	2012-10-26	2013-10-25	Oligonucleotides antisens c-myc et ses procedes d'utilisation pour le traitement de troubles de la proliferation cellulaire

Country Status (4)

Country	Link
EP (1)	EP2912179A4 (fr)
CA (2)	CA2887702C (fr)
HK (1)	HK1214293A1 (fr)
WO (1)	WO2014066851A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2020124043A1 (fr) *	2018-12-13	2020-06-18	Gordon Erlinda M	Procédés d'exploitation d'oncogènes pilotes le long de la voie biologique de la cycline g1 humaine pour thérapie génique du cancer
AU2024287308A1 (en) *	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US5550111A (en)	1984-07-11	1996-08-27	Temple University-Of The Commonwealth System Of Higher Education	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5264423A (en)	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en)	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
AU598946B2 (en)	1987-06-24	1990-07-05	Howard Florey Institute Of Experimental Physiology And Medicine	Nucleoside derivatives
US4924624A (en)	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en)	1987-10-22	1993-02-23	Temple University Of The Commonwealth System Of Higher Education	Encapsulated 2',5'-phosphorothioate oligoadenylates
WO1989009221A1 (fr)	1988-03-25	1989-10-05	University Of Virginia Alumni Patents Foundation	N-alkylphosphoramidates oligonucleotides
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US5194599A (en)	1988-09-23	1993-03-16	Gilead Sciences, Inc.	Hydrogen phosphonodithioate compositions
US5591722A (en)	1989-09-15	1997-01-07	Southern Research Institute	2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en)	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
US5721218A (en)	1989-10-23	1998-02-24	Gilead Sciences, Inc.	Oligonucleotides with inverted polarity
US5177198A (en)	1989-11-30	1993-01-05	University Of N.C. At Chapel Hill	Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5670633A (en)	1990-01-11	1997-09-23	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5459255A (en)	1990-01-11	1995-10-17	Isis Pharmaceuticals, Inc.	N-2 substituted purines
US5587470A (en)	1990-01-11	1996-12-24	Isis Pharmaceuticals, Inc.	3-deazapurines
US5681941A (en)	1990-01-11	1997-10-28	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
US5321131A (en)	1990-03-08	1994-06-14	Hybridon, Inc.	Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
GB9009980D0 (en)	1990-05-03	1990-06-27	Amersham Int Plc	Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es)	1990-05-11	1998-08-01	Microprobe Corp	Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
BR9106702A (pt)	1990-07-27	1993-06-08	Isis Pharmaceuticals Inc	Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5177196A (en)	1990-08-16	1993-01-05	Microprobe Corporation	Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5672697A (en)	1991-02-08	1997-09-30	Gilead Sciences, Inc.	Nucleoside 5'-methylene phosphonates
US5571799A (en)	1991-08-12	1996-11-05	Basco, Ltd.	(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5594121A (en)	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en)	1991-11-26	2000-06-11	Isis Pharmaceuticals Inc	Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en)	1991-11-26	1993-06-28	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
FR2687679B1 (fr)	1992-02-05	1994-10-28	Centre Nat Rech Scient	Oligothionucleotides.
EP0577558A2 (fr)	1992-07-01	1994-01-05	Ciba-Geigy Ag	Nucléosides carbocycliques contenant des noyaux bicycliques, oligonucléotides en dérivant, procédé pour leur préparation, leur application et des intermédiaires
US5476925A (en)	1993-02-01	1995-12-19	Northwestern University	Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en)	1993-03-06	1993-04-21	Ciba Geigy Ag	Chemical compounds
AU6449394A (en)	1993-03-30	1994-10-24	Sterling Winthrop Inc.	Acyclic nucleoside analogs and oligonucleotide sequences containing them
DE4311944A1 (de)	1993-04-10	1994-10-13	Degussa	Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5502177A (en)	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US5519134A (en)	1994-01-11	1996-05-21	Isis Pharmaceuticals, Inc.	Pyrrolidine-containing monomers and oligomers
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5599922A (en)	1994-03-18	1997-02-04	Lynx Therapeutics, Inc.	Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
HUT76094A (en) *	1994-03-18	1997-06-30	Lynx Therapeutics	Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5627053A (en)	1994-03-29	1997-05-06	Ribozyme Pharmaceuticals, Inc.	2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en)	1994-03-31	1997-04-29	Amgen Inc.	Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en)	1994-05-18	1996-06-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pteridine nucleotide analogs as fluorescent DNA probes
US5597909A (en)	1994-08-25	1997-01-28	Chiron Corporation	Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5792747A (en)	1995-01-24	1998-08-11	The Administrators Of The Tulane Educational Fund	Highly potent agonists of growth hormone releasing hormone
US5859233A (en)	1996-02-21	1999-01-12	Lynx Therapeutics, Inc.	Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en)	1996-02-21	1997-11-04	Lynx Therapeutics, Inc.	Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
EP0932698A1 (fr)	1996-03-26	1999-08-04	Lynx Therapeutics, Inc.	Traitements a base d'oligonucleotides et compositions contre les melanomes humains
US6867294B1 (en) *	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
CN1317291C (zh) *	1999-09-10	2007-05-23	杰龙公司	寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
US6784291B2 (en) *	2000-05-04	2004-08-31	Avi Biopharma, Inc.	Splice-region antisense composition and method
CN100393209C (zh) *	2003-09-09	2008-06-11	杰龙公司	用于端粒酶抑制的改性寡核苷酸
WO2008094640A2 (fr) *	2007-01-30	2008-08-07	Geron Corporation	Composés à effets antiadhésifs sur les cellules cancéreuses
CA2784568A1 (fr) *	2009-12-18	2011-06-23	The University Of British Columbia	Particules de lipide destinees a la distribution d'acides nucleiques

2013
- 2013-10-25 CA CA2887702A patent/CA2887702C/fr active Active
- 2013-10-25 EP EP13849097.4A patent/EP2912179A4/fr active Pending
- 2013-10-25 CA CA3201145A patent/CA3201145A1/fr active Pending
- 2013-10-25 WO PCT/US2013/066960 patent/WO2014066851A1/fr not_active Ceased
- 2013-10-25 HK HK16102007.9A patent/HK1214293A1/zh unknown

Also Published As

Publication number	Publication date
HK1214293A1 (zh)	2016-07-22
CA2887702A1 (fr)	2014-05-01
WO2014066851A1 (fr)	2014-05-01
EP2912179A4 (fr)	2016-10-12
EP2912179A1 (fr)	2015-09-02
CA2887702C (fr)	2023-08-01

Legal Events

Date	Code	Title	Description
2023-06-07	EEER	Examination request	Effective date: 20230526
2024-10-02	P11	Amendment of application requested	Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241002
2024-10-02	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241002
2024-10-04	MFA	Maintenance fee for application paid	Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD Year of fee payment: 11
2024-10-04	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241004
2024-10-04	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241004
2025-04-14	P11	Amendment of application requested	Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250414
2025-04-14	P13	Application amended	Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250414
2025-06-20	D15	Examination report completed	Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250620
2025-09-22	MFA	Maintenance fee for application paid	Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 12TH ANNIV.) - STANDARD Year of fee payment: 12
2025-09-22	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250922
2025-09-22	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250922
2025-10-20	P11	Amendment of application requested	Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251020
2025-12-11	P11	Amendment of application requested	Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251211
2025-12-11	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251211

Publication	Publication Date	Title
ES2856844T3 (es)	2021-09-28	Inmunoterapia antitumoral combinada
WO2020205473A1 (fr)	2020-10-08	Compositions et procédés pour le traitement de maladies et troubles associés au kras
JP6949859B2 (ja)	2021-10-13	Ｄｂａｉｔ分子の全身投与によるガンの処置
US9771581B2 (en)	2017-09-26	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
EA023793B1 (ru)	2016-07-29	Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии
JP2022031642A (ja)	2022-02-22	アンチセンスオリゴヌクレオチド
CN113395971A (zh)	2021-09-14	Yap1表达的调节剂
US7273932B1 (en)	2007-09-25	Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
US11813280B2 (en)	2023-11-14	Reducing beta-catenin and IDO expression to potentiate immunotherapy
CA2887702C (fr)	2023-08-01	Oligonucleotides antisens c-myc et ses procedes d'utilisation pour le traitement de troubles de la proliferation cellulaire
TW202214857A (zh)	2022-04-16	新型結合核酸分子及其用途
CN112996568A (zh)	2021-06-18	用于调节mir-10b活性的微小rna化合物和方法
US20210238603A1 (en)	2021-08-05	Beta catenin nucleic acid inhibitor molecule
TW202210633A (zh)	2022-03-16	用於治療癌症之dbait分子與kras抑制劑的組合
JP2023073256A (ja)	2023-05-25	ベータカテニン発現を減少させて免疫療法を強化する
WO2019086626A1 (fr)	2019-05-09	Miarn et combinaisons de ceux-ci pour leur utilisation dans le traitement de néoplasies à lymphocytes b humaines
JP2004528851A (ja)	2004-09-24	上皮成長因子受容体のアンチセンスオリゴヌクレオチド
JP2017508467A (ja)	2017-03-30	がんを処置するためのｒｎａを含む医薬組成物および使用
US20200330606A1 (en)	2020-10-22	Modulation of structural maintenance of chromosome-1 expression